Table 3.

Summary of boceprevir pharmacokinetic parameters^*

Pharmacokinetic parameters	Cohort 1 dolutegravir + boceprevir (n = 15)	Boceprevir alone‡
AUC0–τ (μg h ml−1)	4.63 (14)	5.408
Cmax (μg ml−1)	1.64 (16)	1.723
Cτ (μg ml−1)	0.08 (35)	–
Cmin (μg ml−1)	0.07 (23)	0.08
t1/2 (h)	1.31 (14)	–
Tmax (h)†	2.0 (1.0–3.0)	–

Abbreviations are as follows: AUC_0–τ, area under the concentration–time curve from time 0 to the end of the dosing interval; C_max, observed maximal plasma concentration; C_min, observed minimal plasma concentration; C_τ, 24 h postdose concentration at steady state; t_1/2, apparent terminal half-life; T_max, time to maximal plasma concentration.

^*Geometric mean (between subject coefficient of variation, %CVb).

^†Presented as median (range).

^‡Boceprevir package insert, 2013.